Guggenheim Maintains Buy on Ardent Health, Raises Price Target to $14

Benzinga Newsdesk www.benzinga.com Positive 66.3%

Neg 0% Neu 0% Pos 66.3%

Guggenheim analyst Jason Cassorla maintains Ardent Health (NYSE:ARDT) with a Buy and raises the price target from $13 to $14.